购物车
- 全部删除
- 您的购物车当前为空
NXT629 is a selective and competitive antagonist of PPAR-α(human PPARα with an IC50 of 77 nM).
为众多的药物研发团队赋能,
让新药发现更简单!
NXT629 is a selective and competitive antagonist of PPAR-α(human PPARα with an IC50 of 77 nM).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 3,290 | 现货 | |
5 mg | ¥ 5,390 | 6-8周 | |
25 mg | ¥ 11,700 | 6-8周 | |
50 mg | ¥ 15,300 | 6-8周 | |
100 mg | ¥ 19,500 | 6-8周 | |
1 mL x 10 mM (in DMSO) | ¥ 7,260 | 6-8周 |
产品描述 | NXT629 is a selective and competitive antagonist of PPAR-α(human PPARα with an IC50 of 77 nM). |
靶点活性 | PPARα (human):77 nM, PPARδ (human):6 μM, ERβ:15.2 μM, PPARγ (human):15 μM, GR:32.5 μM |
体外活性 | NXT629 is a potent and selective antagonist of PPAR-α(human PPARα,IC50 of 77 nM), shows high selectivity over other nuclear hormone receptor, [2]. |
体内活性 | NXT629 has poor oral bioavailability in mice and rats.?NXT629 (30 mg/kg, i.p., daily for 6 weeks) delays growth of subcutaneous SKOV-3 tumors in nude mice, inhibits growth of subcutaneous B16F10 tumors in C57Bl/6 mice.?NXT629 (30 mg/kg, i.p.) is weakly anti-angiogenic against FGF-induced angiogenesis.?NXT629 (3, 30 mg/kg, i.p.) inhibits experimental metastasis of B16F10 melanoma cells to the mouse lung[2]. |
分子量 | 609.78 |
分子式 | C35H39N5O3S |
CAS No. | 1454925-59-7 |
Smiles | CCn1c(CCCc2ccc(cc2)-c2ccc(NS(=O)(=O)c3ccccc3)cn2)nn(Cc2ccc(cc2)C(C)(C)C)c1=O |
密度 | 1.20 g/cm3 (Predicted) |
存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 125 mg/mL (204.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容